2009
Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer
Deshpande HA, Gettinger S, Sosa JA. Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer. Core Evidence 2009, Volume 4: 43-48. PMID: 20694064, PMCID: PMC2899774, DOI: 10.2147/ce.s5996.Peer-Reviewed Original ResearchThyroid cancerVascular endothelial growth factor receptor 1Common grade 3Refractory thyroid cancerUse of axitinibGood tolerability profilePhase II studyAdvanced thyroid cancerGrowth factor receptor 1Greater side effectsFactor receptor 1Growth factor receptorStable diseaseTolerability profileII studyHistological typeCancer deathGrade 3New small molecule inhibitorsRare diseaseSide effectsSmall molecule inhibitorsResponse rateNew treatmentsReceptor 1
2008
Lung Neoplasms
Detterbeck F, Gettinger S, Socinski M. Lung Neoplasms. 2008, 1491-1523. DOI: 10.1007/978-0-387-68113-9_72.Peer-Reviewed Original Research
2007
Treatment of Lung Cancer in Older Patients
Tanoue LT, Gettinger S. Treatment of Lung Cancer in Older Patients. Clinics In Chest Medicine 2007, 28: 735-749. PMID: 17967291, DOI: 10.1016/j.ccm.2007.08.003.Peer-Reviewed Original Research